Welcome
Support Centre
05 July 2008 
ISRCTN Register - International Standard Randomized Controlled Trial Number
Trial registration
Unique identification scheme
International databases
home  |   my details  |   ISRCTN Register  |   mRCT  |   UKCTG  |   links  |   information  |   press
Find trials
ISRCTN Register
tips on searching

Registration
New application
Updating record

Information
introduction
governing board
ISRCTN FAQs
data set
letter of agreement
request information
guidance notes

[ Print-friendly version ]
Cognitive Behavioural Therapy (talking therapy) for Alzheimer's Carers
ISRCTN ISRCTN77610095
ClinicalTrials.gov identifier
Public title Cognitive Behavioural Therapy (talking therapy) for Alzheimer's Carers
Scientific title Cognitive behavioural therapy (CBT) for carers of patients with Alzheimer's disease: a randomised controlled trial
Acronym The CBTAC Study
Serial number at source N/A
Study hypothesis Many individuals with Alzheimer's disease live in their own homes, cared for by a member of their family. Providing such care can be a source of significant stress. Carers can present with depression, anxiety, loneliness and other psychological strain. The present study seeks to evaluate the efficacy of CBT in treating psychological distress in a group of Alzheimer's carers.

Hypothesis:
12 sessions of cognitive behavioural therapy (CBT) will significantly reduce the Geriatric Depression Scale scores in carers of patients with Alzheimer's disease, in comparison with a group receiving treatment as usual.
Ethics approval Ethics approval pending from Leeds East Research Ethics Committee as of 19/03/2008. To be submitted April 2008.
Study design Prospective, single-centre, unblinded, randomised controlled study
Countries of recruitment United Kingdom
Disease/condition/study domain Psychological distress in Alzheimer's carers
Participants - inclusion criteria 1. Primary carer of an individual with Alzheimer's disease
2. Willing to engage actively in 10 - 12 weekly therapy sessions, over a three month period
3. Willing to complete self report questionnaires before treatment starts, at three months and six months after entering the study
4. Aged 18 - 90 years, either sex
Participants - exclusion criteria 1. Carers not fluent in English (due to nature of the treatment)
2. Evidence of cognitive impairment, assessed as a Mini-Mental State Examination score of less than 26/30
3. Currently prescribed certain psychotropic medication, i.e., antipsychotics, mood stabilisers, hypnotics and sedatives. Those receiving antidepressants will not be excluded
4. The person they care for with Alzheimer's disease is under 65 (pre-senile dementia)
Anticipated start date 01/07/2008
Anticipated end date 01/02/2009
Status of trial Ongoing
Patient information material Not available in web format, please use the contact details below to request a patient information sheet
Target number of participants 40 participants will be recruited
Interventions The treatment group will receive between 10 - 12 sessions of weekly CBT over a three-month period. The sessions will last for 50 minutes each, they will see the same therapist every week. Participants will be asked to complete self report questionnaires before treatment starts, after three months of treatment and again after six months of the start of the study. These questionnaires aim to indicate their distress and will be compared to similar measures in the treatment as usual group.

The treatment as usual group (control group), will receive support already offered to Alzheimer's carers in the area. This consist of a carer appointment with nurses, a monthly support group with other carers, and a monthly Forget Me Not Cafe, a support meeting with the person they care for. The participants in the control group will complete the same questionnaires as those in the treatment group, at similar time intervals.

The questionnaires used are:
1. Geriatric Depression Scale
2. Carer Strain Index
3. Carer Burden Inventory score

All participants will also complete a Mini-Mental State Examination to assess their cognition as to be included in the study, as well as a socio-demographic questionnaire at the beginning.

Total duration of follow-up for both treatment and control arm will be six months from start of treatment.
Primary outcome measure(s) 12 sessions of CBT will significantly reduce the Geriatric Depression Scale scores in carers of patients with Alzheimer's disease, in comparison with a group receiving treatment as usual. For the Geriatric Depression Rating Scale (GDS) an improvement of a score out of 15 will be measured, where a score greater than 5 indicates probable depression.

These measures will be taken in all participants (treatment and control groups), prior to start of treatment, after 3/12 and again after 6/12 of start of treatment, thus T0, T3 and T6. These scores will then be compared to detect within participant and between group differences at three different time points.
Secondary outcome measure(s) 1. 12 sessions of CBT will significantly reduce the Carer Strain Index scores in carers of patients with Alzheimer's disease, in comparison with a group receiving treatment as usual. For the Carer Strain Index score (CSI) an improvement of a score out of 12 will be measured, where a score greater than 7 indicates a high level of strain.
2. 12 sessions of CBT will significantly reduce the Carer Burden Inventory scores in carers of patients with Alzheimer's disease, in comparison with a group receiving treatment as usual. For the Carer Burden Inventory score (CBI) an improvement of a score out of 88 will be measured, where a score between 61 - 88 indicates severe burden, 41 - 60 moderate to severe burden, 21 - 40 mild to moderate burden and 0 - 20 indicates little or no burden.

These measures will be taken in all participants (treatment and control groups), prior to start of treatment, after 3/12 and again after 6/12 of start of treatment, thus T0, T3 and T6. These scores will then be compared to detect within participant and between group differences at three different time points.
Sources of funding Investigator initiated and funded (UK)
Trial website
Publications
Contact name Dr  Sonja  Kruger
  Address Towngate House Hospital
1 Towngate Close
OFF Queensway
Guiseley
  City/town Leeds
  Zip/Postcode LS20 9LA
  Country United Kingdom
Sponsor Leeds Partnerships NHS Foundation Trust (UK)
  Address Twenty One Fifty
Thorpe Park
  City/town Leeds
  Zip/Postcode LS15 8ZB
  Country United Kingdom
  Sponsor website: http://www.leedsmentalhealth.nhs.uk/
Date applied 19/03/2008
Last edited 04/04/2008
Date ISRCTN assigned 04/04/2008
Submit your trial protocol Top studies in medical research Submit to Trials journal
© ISRCTN


BioMed Central